Coopersurgical Patent-Cliff Exposure & CMS Drug Spending Portfolio
Coopersurgical (US): 4 reconciled FDA prescription therapies (1.1% 2025 to 2030 cliff risk), $45.7M 2024 CMS Part D & Medicaid spend, and $1,085 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 4 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 1.1% |
| Primary Portfolio LOE Date | 2027-01-01 |
| 2024 CMS Total Public Spend | $45.7M |
| 2024 Medicare Part D Spend | $372 |
| 2024 Medicaid Spend | $45.7M |
| California HCAI SB 17 Filings | Specialty launch notice ($1,085 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for CooperCompanies across sibling Meru public-data platforms.